SESSION R.A. II (President and CEO) sold 1.0% of their position (85.87K shares) of TAYSHA GENE THERAPIES, INC. on the open market
Open‑market sale worth $60.8K — a minor trim. Review remaining holdings and any 10b5‑1 plan disclosures.
S · 2 sales
Filed: 7/14/2023ACC: 0000950170-23-032986
DirectorOfficer10% Owner· President and CEO
Since Sep 2020
-85.87K
Net shares
Net seller
$60.8K
Total sold
2
Open market trades
0B · 2S
2
Total transactions
85.87K disposed
Non-Derivative Transactions2
Common Stock
Direct
Shares
−80.53K
Price / share
$0.71
Trade value
$57.03K
% of position
0.9%
7/12/2023
8.96M→8.88M
Common Stock
Direct
Shares
−5.34K
Price / share
$0.70
Trade value
$3.74K
% of position
0.1%
7/13/2023
8.88M→8.87M
Total
Net shares
−85.87K
Net value
-$60.77K
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Direct | 7/12/2023 | S · Sale | −80.53K | $0.71 | $57.03K | 0.9% | 8.96M | 8.88M |
| Common Stock Direct | 7/13/2023 | S · Sale | −5.34K | $0.70 | $3.74K | 0.1% | 8.88M | 8.87M |
| Total | −85.87K | -$60.77K | ||||||
Derivative Transactions0
No derivative transactions reported
Non-Derivative Holdings (Post-Transaction)2
Common Stock
IndirectShares owned141.09K
Common Stock
IndirectShares owned141.09K
Total
282.18K indirect282.18K
| Security Title | Shares Owned | Ownership Type |
|---|---|---|
| Common Stock | 141.09K | Indirect |
| Common Stock | 141.09K | Indirect |
| Total | 282.18K | 282.18K indirect |
Derivative Holdings (Post-Transaction)0
No derivative holdings reported